Epcoritamab’s trial win leaves the treatment comparison open
By OnTheRice · Sources and limitations · Report a correction
Genmab and AbbVie reported better disease control against R-CHOP chemotherapy. The trial did not test an already approved alternative, so the commercial and treatment comparison remains open.
Source confidenceNot assessed
What’s changing?
The FDA approved Polivy with R-CHP in 2023 for specified untreated lymphoma patients with IPI scores of at least 2. The new trial did not compare against that combination.
Key points
- Genmab and AbbVie reported better disease control against R-CHOP chemotherapy.
- The trial did not test an already approved alternative, so the commercial and treatment comparison remains open.
What could change this view?
- This is an early summary from an ongoing trial. The use is investigational. Hazard reduction is a relative time-to-event measure, not a cure rate or an absolute survival gain.
Bottom line
More likely direction: BULLISH over the next 24 hours.
This is based on the information recorded with this signal.
How likely is this call? · Three frameworks
AbbVie (ABBV) · BULLISH
Probability not recorded at publication. This earlier call is preserved without adding a hindsight estimate.
Genmab (GMAB) · BULLISH
Probability not recorded at publication. This earlier call is preserved without adding a hindsight estimate.
Evidence behind this view
Checks whether separate pieces of evidence support the same view.
Recorded connection
The FDA approved Polivy with R-CHP in 2023 for specified untreated lymphoma patients with IPI scores of at least 2. The new trial did not compare against that combination.
We have not established a separate count of independent evidence clusters for this card. Several reports may rely on the same event or data provider.
What past price moves show
Compares today’s price moves with recorded past patterns.
No asset-specific historical pattern test is recorded separately for this card.
Evidence against this view
Shows evidence and risks that could challenge this view.
Recorded opposing evidence and risks
This is an early summary from an ongoing trial. The use is investigational. Hazard reduction is a relative time-to-event measure, not a cure rate or an absolute survival gain.
Why the direction changed
Explains recorded changes from expecting a rise to expecting a fall, or the reverse.
No documented bullish-to-bearish or bearish-to-bullish change is available for this card. We keep the original call and its time unchanged.
What people say vs the facts
Compares recorded public discussion with checked market facts.
No separate Reddit or public-discussion comparison with verified market data is recorded for this card. We cannot treat social attention as proof of a market move.
How past forecasts performed
Shows recorded forecast results and what they can teach us.
Recorded outcomes for this signal: 1 HIT, 1 MISS, 0 other or pending. These counts are not a forecast probability.
No tested mapping from evidence combinations to future success is recorded for this card. Confidence in sources and past outcomes do not establish a calibrated probability.
Sources, original wording and price checks
Original research record
The companies reported a 51% lower hazard of progression or death with epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The primary analysis covered IPI risk scores of 3–5; the wider 2–5 group was a separate analysis.
The FDA approved Polivy with R-CHP in 2023 for specified untreated lymphoma patients with IPI scores of at least 2. The new trial did not compare against that combination.
OTR’s view: the result supports a possible first-line expansion, but does not rank it against every available treatment.
Investors: examine full safety and efficacy data, the eventual label and evidence relevant to existing alternatives. Do not compare separate trials as if they were head-to-head.
This is an early summary from an ongoing trial. The use is investigational. Hazard reduction is a relative time-to-event measure, not a cure rate or an absolute survival gain.
Full data and regulatory approval would strengthen the development case.
Material safety concerns, weaker full results or rejection would weaken it.
GMAB and ABBV: BULLISH / WATCH for the potential indication, with uptake and company-level value unverified. Watch full data and regulatory review. NO ENTRY.
Published
First published through Sites 06 Oct 2026, 12:18:23 SGT
24-hour check
- AbbVie (ABBV)BULLISH ✓ HITPrice 1: 265.76 USD
At publication: 06 Oct 2026, 12:18:23 SGT
Price 2 (+24h): 266.69 USD
At +24h: 07 Oct 2026, 12:18:23 SGT
Change: +0.350%
Price 1 source: 06 Oct 2026, 04:01:00 SGT (offset -29843.693075 s)
Price 2 source: 07 Oct 2026, 04:03:00 SGT (offset -29723.693075 s)First published through Sites: 06 Oct 2026, 12:18:23 SGTCall and evidence
BULLISH / WATCH
The price rose between the nearest observations to publication and +24 hours; the bullish direction was correct.
Price series: ABBV · NYSE. Nearest available one-minute candle opening price to each fixed endpoint. Offsets are disclosed; original call and deadline are unchanged.
Price 1 · at publicationExact endpoint: 06 Oct 2026, 12:18:23 SGT
265.76 USD · Nearest intraday candle (approximation)
Source quote: 265.76 USD · 06 Oct 2026, 04:01:00 SGT
Source observation ↗Offset from required time: -29843.693075 seconds. Negative means before; positive means after.
One-minute candle start; candle opening price. This is an approximation to the requested instant.
Price 2 · exactly +24 hoursExact endpoint: 07 Oct 2026, 12:18:23 SGT
266.69 USD · Nearest intraday candle (approximation)
Source quote: 266.69 USD · 07 Oct 2026, 04:03:00 SGT
Source observation ↗Offset from required time: -29723.693075 seconds. Negative means before; positive means after.
One-minute candle start; candle opening price. This is an approximation to the requested instant.
Change: +0.93 USD (+0.350%). The price rose between the nearest observations to publication and +24 hours; the bullish direction was correct.
Correction: Owner-requested full recalculation using nearest available intraday prices and disclosed offsets; includes previously settled calls. The previous result remains in the immutable assessment history.
- Genmab (GMAB)BULLISH ✕ MISSPrice 1: 38.52500153 USD
At publication: 06 Oct 2026, 12:18:23 SGT
Price 2 (+24h): 37.8 USD
At +24h: 07 Oct 2026, 12:18:23 SGT
Change: -1.882%
Price 1 source: 06 Oct 2026, 03:59:00 SGT (offset -29963.693075 s)
Price 2 source: 07 Oct 2026, 04:00:00 SGT (offset -29903.693075 s)First published through Sites: 06 Oct 2026, 12:18:23 SGTCall and evidence
BULLISH / WATCH
The price fell between the nearest observations to publication and +24 hours; the bullish direction was incorrect.
Price series: GMAB · NasdaqGS. Nearest available one-minute candle opening price to each fixed endpoint. Offsets are disclosed; original call and deadline are unchanged.
Price 1 · at publicationExact endpoint: 06 Oct 2026, 12:18:23 SGT
38.52500153 USD · Nearest intraday candle (approximation)
Source quote: 38.52500153 USD · 06 Oct 2026, 03:59:00 SGT
Source observation ↗Offset from required time: -29963.693075 seconds. Negative means before; positive means after.
One-minute candle start; candle opening price. This is an approximation to the requested instant.
Price 2 · exactly +24 hoursExact endpoint: 07 Oct 2026, 12:18:23 SGT
37.8 USD · Nearest intraday candle (approximation)
Source quote: 37.8 USD · 07 Oct 2026, 04:00:00 SGT
Source observation ↗Offset from required time: -29903.693075 seconds. Negative means before; positive means after.
One-minute candle start; candle opening price. This is an approximation to the requested instant.
Change: -0.72500153 USD (-1.882%). The price fell between the nearest observations to publication and +24 hours; the bullish direction was incorrect.
Correction: Owner-requested full recalculation using nearest available intraday prices and disclosed offsets; includes previously settled calls. The previous result remains in the immutable assessment history.
What changed
Recorded public historyGenmab and AbbVie reported better disease control against R-CHOP chemotherapy. The trial did not test an already approved alternative, so…
This is the first recorded public view. Further public updates will appear here.
- Epcoritamab’s trial win leaves the treatment comparison open
Genmab and AbbVie reported better disease control against R-CHOP chemotherapy. The trial did not test an already approved alternative, so the commercial and treatment comparison remains open.
First published by OTR: 6 Oct, 12:18 SGTPublished by OTR: 6 Oct 2026, 12:18 SGT
Why the view changed
This is the first recorded view. Future source-backed updates will appear here.
Evidence, memory & review 2 linked sources
What changed: The companies reported a 51% lower hazard of progression or death with epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The primary analysis covered IPI risk scores of 3–5; the wider 2–5 group was a separate analysis.
Named assets or actors: Genmab (GMAB), AbbVie (ABBV)
Directional takeaway: BULLISH / WATCH
OTR reasoning: The FDA approved Polivy with R-CHP in 2023 for specified untreated lymphoma patients with IPI scores of at least 2. The new trial did not compare against that combination.
Counterpoint: This is an early summary from an ongoing trial. The use is investigational. Hazard reduction is a relative time-to-event measure, not a cure rate or an absolute survival gain.
Source trail
- EPCORE DLBCL-2 topline trial results ↗Genmab and AbbVie issuer release via GlobeNewswire5 October 2026 14:49 ET (18:49 UTC, EDT); minute precision · source clock as displayed
- FDA approved Polivy indication ↗US FDACurrent database; update time not shown · source clock as displayed
Review status: APPROVED
No score or probability is presented.